← Back

Wire · opportunities

Anixa Biosciences and Curia will Develop Final Formulation for Breast Cancer Vaccine in ...

Published

18 November 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at prnewswire.com →

◆ Verified

Fusion42 · 18 November 2026 · Fusion42 review

Anixa Biosciences partners with Curia to develop a stable, scalable formulation for its investigational breast cancer vaccine in preparation for Phase 2 clinical trials and potential commercialisation.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You can now lean on Curia's expertise to move your cancer vaccine from early safety testing to scalable clinical formulations ready for Phase 2. This widens your path to commercial manufacture and signals serious momentum for breast cancer immunotherapy.

◆ Coverage

1 source · 18 Nov 2026

◆ Related on Wire

◆ Topics

Biotechcancer-vaccineformulation-developmentclinical-trialsbiotechnologycdmo-partnership